Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study
Infection · 2024
DOI: 10.1007/s15010-024-02250-9 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Infection, 2024. Verfasst von Giuseppe Lapadula und 8 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy. giuseppe.lapadula@unimib.it. Hauptthemen laut MEDLINE: COVID-19, Antibodies, Viral, SARS-CoV-2, Spike Glycoprotein, Coronavirus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Milano - Bicocca.
Abstract (Originalsprache)
Purpose
Antibodies against SARS-CoV-2 spike (anti-S) may confer protection against symptomatic COVID-19. Whether their level predicts progression among those with COVID-19 pneumonia remains unclear.
Methods
We conducted a retrospective cohort study to assess predictors of anti-S levels and whether anti-S titer is associated with death or mechanical ventilation (MV). Adults hospitalized for COVID-19 pneumonia between July 2021 and July 2022 were enrolled if anti-S had been measured within 72 h of admission. Predictors of anti-S level were explored using multivariable quantile regression. The association between anti-S levels and 30-day death/MV was investigated via multivariable logistic regression. Analyses were stratified by vaccine status.
Results
The median anti-S level was 1370 BAU/ml in 328 vaccinated and 15.5 BAU/ml in 206 unvaccinated individuals. Among the vaccinated, shorter symptom duration ( p = 0.001), hematological malignancies ( p = 0.002), and immunosuppressive therapy ( p = 0.004) were associated with lower anti-S levels. In the unvaccinated group, symptom duration was the only predictor of anti-S levels ( p < 0.001). After 30 days, 134 patients experienced death or MV. Among vaccinated individuals, higher anti-S levels correlated significantly with lower death/MV risk (per log 2 increase, OR 0.88, 95%CI 0.81–0.97), irrespective of age and solid malignancies. Among unvaccinated, a marginally protective effect was observed (OR 0.86, 95%CI 0.73–1.01), independent of age, immunosuppressive therapy, and diabetes. Adjustment for monoclonal antibody treatment strengthened the association (OR 0.81, 95%CI 0.68–0.96).
Conclusion
This study suggests that levels of anti-S antibodies can predict critical or fatal outcomes in COVID-19 pneumonia patients, regardless of vaccination. Whether anti-S Ab could guide risk assessment and vaccination boosting merits further evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy. giuseppe.lapadula@unimib.it.
- School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. giuseppe.lapadula@unimib.it.
- School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
- Bicocca Bioinformatics Biostatistics and Bioimaging Center-B4, University of Milano-Bicocca, Milan, Italy.
- Microbiology Unit, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy.
- Infectious Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
Förderung
- Università degli Studi di Milano - Bicocca
Zitieren
APA
Lapadula, G., Mezzadri, L., Lo Cascio, G., Antolini, L., Malandrin, S., Ranzani, A., Limonta, S., Cavallero, A., & Bonfanti, P. (2024). Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study. Infection. https://doi.org/10.1007/s15010-024-02250-9
Vancouver
Lapadula G, Mezzadri L, Lo Cascio G, Antolini L, Malandrin S, Ranzani A, et al. Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study. Infection. 2024. doi:10.1007/s15010-024-02250-9
BibTeX
@article{Lapadula2024,
author = {Lapadula, Giuseppe and Mezzadri, Luca and Lo Cascio, Giustina and Antolini, Laura and Malandrin, Sergio and Ranzani, Alice and Limonta, Silvia and Cavallero, Annalisa and Bonfanti, Paolo},
title = {Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study},
journal = {Infection},
year = {2024},
doi = {10.1007/s15010-024-02250-9}
}
EUVIMED